Methods and compositions for treating and preventing mucositis

• US 6,458,777 B1
• Filed: 03/09/1999
• Issued: 10/01/2002
• Est. Priority Date: 03/13/1998
• Status: Expired due to Fees

• Current Assignee: Mucosal Therapeutics, LLC
• Original Assignee: Mucosal Therapeutics, LLC
• Inventors: Sonis, Stephen T., Fey, Edward G.
• Primary Examiner(s): Seidel, Marianne C.
• Assistant Examiner(s): DELACROIX MUIRHEI, CYBILLE
• Application Number:
  US09/265,299
• Time in Patent Office: 1,302 Days
• Field of Search: 514/152, 514/899, 424/464
• US Class Current: 514/152
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/235 having an aromatic ring attached to a carboxyl group
• CPC Class Codes: A61K 31/454 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed.

Claims

1. A method of treating a patient undergoing radiation treatment or chemotherapy to prevent or reduce the severity of mucositis comprising administering to the patient a formulation comprising an active agent, wherein the active agent consists essentially of an effective amount of a tetracycline to decrease duration or severity of mucositis when applied to the mucosal surface.

2. The method of claim 1 wherein the tetracycline is in a concentration of between 0.01 and 1 mg/ml.

3. The method of claim 2 wherein the tetracycline is in a concentration of between 0.1 and 1.0 mg/ml.

4. The method of claim 1 wherein the formulation is selected from the group consisting of a oral rinse, tablet, lozenge, paste and gel.

5. The method of claim 1 wherein the formulation is administered to the patient one day before the patient is treated with chemotherapy or radiation.

6. The method of claim 1 wherein the formulation is administered at least daily to a patient undergoing radiation or chemotherapy.

7. The method of claim 1 wherein the patient is a cancer patient.